Objectives: To study the phenotype and phylogenetic relatedness of invasive Streptococcus pneumoniae strains isolated in Portugal.
Introduction
The emergence of drug-resistant strains of Streptococcus pneumoniae is a growing problem worldwide. 1 In Europe, the prevalence of macrolide resistance is increasing in non-invasive strains mainly in southern countries. 2 In Portugal, the prevalence of erythromycin resistance of S. pneumoniae was stable during 1989-1993. 3 To our knowledge, no further data have been published since. Molecular typing analyses show that only a small number of dominant clones are responsible for the spread of antibiotic resistance worldwide. 4 We analysed macrolide usage and the genetic background of invasive S. pneumoniae clones of serotype 14 responsible for the increase in erythromycin resistance in Portugal. We also evaluated their relationship with drug-resistant clones in other countries.
Materials and methods

Clinical isolates
During January 1999-June 2002, 614 consecutive and non-repetitive invasive strains of S. pneumoniae were collected in the Antibiotic Resistance Unit at the National Institute of Health in Lisbon, in a multicentre study with 24 participating hospitals. The strains were isolated from blood, cerebrospinal fluid and pleural liquid from clinically ill patients. 
Phenotypic characterization
Antimicrobial use data
National outpatient sale data [taken from International Medical Statistics (IMS Health, Portela, Portugal)] were used for macrolides/ lincosamides (J01F) (azithromycin, clarithromycin, clindamycin, erythromycin, lincomycin, midecamycin, roxithromycin, spiramycin, telithromycin) for the period 1994-2002. The data were normalized to the Anatomic Therapeutic Classification system proposed by WHO. 8 The number of packages consumed annually per 1000 inhabitants was used to enable the comparison of macrolide use over time in the same geographic area. The correlation between antimicrobial consumption and rates of macrolide resistance was assessed by the Spearman correlation coefficient applying the natural logarithm to the antimicrobial resistance, in order to have a linear relation. The null hypothesis was rejected for P values of <0.01.
Genotypic characterization
All erythromycin-resistant strains of serotype 14 (n = 25) were investigated by PFGE and multilocus sequence typing (MLST) (eBURST).
9,10 PFGE DNA fingerprints and MLST data were combined and analysed using Bionumerics software (version 3.0) (Applied Maths, St-Martens-Latem, Belgium). eBURST is an algorithm for displaying the relationships between closely related isolates of a bacterial species or population. This analysis was used to deter- mine the main clonal complexes (CC) and the order of sequence types (ST) within CCs from MLST data. 10 The algorithm predicts the descent from the founding genotype to the other genotypes in the group, displaying the output as a radial diagram, centred on the predicted founding genotypes. All strains of serotype 14 (n = 274) in the pneumococcal MLST database were included in the analysis, 10 to establish phylogenetic relationships between the erythromycinresistant strains of this study and the principal CCs of serotype 14 already described.
Results and discussion
Phenotypic characterization
The MICs of 614 strains isolated in Portugal in 1999, 2000, 2001 and the first 6 months of 2002 were determined. The MICs of erythromycin were in the range 0.5 -> _ 64 mg/L and for clindamycin in the range 2-> _ 64 mg/L. Overall, 13.6% and 10.1% of strains were resistant to erythromycin (MIC > _ 0.5 mg/L) and clindamycin (MIC > _ 0.5 mg/L), respectively. We showed an emerging macrolide resistance compared with the period 1989-1993:
3 when 1.9% and 1.4% of strains were resistant to erythromycin and clindamycin, respectively. This observation is consistent with trends in other countries. 2 In our study, the majority of erythromycin-resistant strains (74%) were also resistant to clindamycin and so had the MLS B phenotype, as in the period 1989-1993 (76%).
Most erythromycin-resistant strains were in one of three serotypes: 14 (31.0%), 6B (26.2%) and 19F (14.3%). The most common multidrug resistance phenotypes were: (i) penicillin, tetracycline, erythromycin and clindamycin, mainly for serotypes 6B, 19F, 14 (in descending order); (ii) tetracycline, erythromycin, clindamycin and chloramphenicol, for serotypes 6B and 19F; and (iii) penicillin, ceftriaxone, cefotaxime, tetracycline, erythromycin and clindamycin only for serotype 14. (Figure 1a) .
A strong correlation was found between the resistance to erythromycin and the use of azithromycin (r = 0.900, P = 0.001) (Figure 1b) . These results suggest that the increase in azithromycin use is associated to the increase in macrolide resistance in S. pneumoniae.
Genotypic characterization
Genotypic characterization of the largest serotype contributor (serotype 14) showed that the increase in erythromycin resistance is due to clones included in two CCs, formed by five STs (Figures 2 and 3) . The CC1 was formed by ST156, ST143 and ST1042 (Figure 2 ). MLST showed that strains of ST143 are double loci variants from ST156 (Figure 3a) . Isolate 3569 is a Figure 2 . Properties and phylogenetic relationships based on MLST and PFGE data from 25 erythromycin-resistant strains with serotype 14. The Dice bandbased similarity coefficient was used for PFGE pattern analysis, with a band position tolerance of 1% and an optimization of 1%. PFGE DNA fingerprints and MLST data were combined and analysed using Bionumerics software. The dendrogram was constructed by the unweighted pair-group method with average linkages using the composite data set of MLST and the PFGE patterns. Bl, blood; Pl, pleural liquid; CSF, cerebrospinal fluid; Pen, penicillin; Ctx, cefotaxime; Cft, ceftriaxone; Tet, tetracycline; Ery, erythromycin; Cli, clindamycin; Clo, chloramphenicol; Of, ofloxacin; Cip, ciprofloxacin. previously undescribed single locus variant (SLV) of ST156, and was assigned to ST1042 (Figure 3a) . CC2 consisted of ST15 and ST9 (Figure 2 ). ST9 is an SLV from ST15 (Figure 3b ). eBURST analysis showed that CC1 and CC2 found in this study (Figure 2) are part of the lineages 3 ( Figure 3a ) and 2 (Figure 3b) , respectively. These lineages were found among 121 STs (grouped into 10 lineages) from all serotype 14 strains in the pneumococcal MLST database.
Erythromycin-resistant clone ST156 present in Portugal is a serotype 14 variant of the erythromycin-susceptible international clone Spain 9V À3 (Spain 9V À3-14). 9, 11 This variant spread internationally, but most isolates are susceptible to macrolides, as identified in the MLST database (Figure 4) . 10 ST156 found in this study has been described in different countries, but in Uruguay it was described as being resistant to erythromycin. 10, 11 eBURST analysis of all strains of serotype 14 in the pneumococcal MLST database may indicate that ST156 was the first in the evolutionary pathway of CC1 (the ancestral type) (Figure 3a) . The greater variability of PFGE and resistance patterns of ST156 than of ST143 in our sample is consistent with this possibility. ST144, not present among our strains (SLV variant of ST156), is a putative ancestor of ST143.
ST143 is the biggest clonal lineage in our sample (eight of 25 strains). This lineage has previously been described in Poland: all but one were erythromycin-susceptible isolates. 10 Possibly this Portuguese clone was imported from that country. ST330 is an erythromycin-resistant clonal lineage, and is an SLV of ST143 (Figure 3a) . 10 eBURST analysis suggests that this ST, originally from a subpopulation of ST143 erythromycin-resistant strains, is probably of the same population as found in our study, and is genetically more distant from ST156. The new multidrugresistant clonal lineage ST1042 could be a result of a recombinational event at the ddl locus.
Our ST9 strains had the same allelic profile and resistance pattern as England 14 À9, an international erythromycin-resistant clone. 4 This clone of serotype 14 has been described in the UK, Italy, Argentina, Germany 10 and in carriers in Portugal. 12 In Australia, this clone was found in susceptible and resistant strains, as identified in the updated pneumococcal MLST database. 10 The clonal lineage ST15 we found among Portuguese invasive strains has also been described in the UK, Taiwan, Italy, Hong Kong, Germany 10 and in Portuguese carriers. 12 Both susceptible and resistant strains of this ST have been described in Brazil, and susceptible strains have been found in the Netherlands. 10 eBURST analysis shows that ST15 might be the ancestral type for CC2 (Figure 3b ). This is consistent with the diversity of ST15 resistance patterns in our study (erythromycin, erythromycin plus clindamycin, penicillin plus erythromycin plus clindamycin, and tetracycline plus erythromycin plus clindamycin) compared with ST9 (only erythromycin resistance pattern). Possibly ST9 diverged from ST15 very recently, differing as attested by a single nucleotide polymorphism in the xpt gene sequence. This is reinforced with the PFGE data, which showed that ST15 and ST9 are phylogenetically very close.
Four STs described in this work (ST156, ST143, ST15 and ST9) are putative founders of major clonal groups and subgroups within serotype 14; they probably already existed in Portugal prior to the increase in erythromycin resistance. Both erythromycin-resistant and susceptible strains from invasive diseases are found in the same clonal lineage in several countries, including Portugal (data not shown). As the STs we describe include members of the major internationally disseminated clones of serotype 14 susceptible to macrolides, this also suggests that the resistance mechanisms were acquired locally (Figure 4) .
To our knowledge, this study is the first report of the genetic relatedness of invasive pneumococcal clones responsible for the emergence of erythromycin resistance in Portugal. This study suggests that azithromycin use is an important selection factor for the spread of these clones in Portugal, which is also associated with the increase in macrolide resistance. This also provides a contribution to the understanding of the spread of these antibiotic-resistant clones in an international context. 
